Celgene Corp. Company Profile (NASDAQ:CELG)

About Celgene Corp.

Celgene Corp. logoCelgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CELG
  • CUSIP: 15102010
Key Metrics:
  • Previous Close: $107.95
  • 50 Day Moving Average: $109.94
  • 200 Day Moving Average: $104.68
  • 52-Week Range: $93.05 - $128.39
  • Trailing P/E Ratio: 45.23
  • Foreward P/E Ratio: 16.64
  • P/E Growth: 0.87
  • Market Cap: $82.95B
  • Outstanding Shares: 775,114,000
  • Beta: 1.24
Additional Links:
Companies Related to Celgene Corp.:

Analyst Ratings

Consensus Ratings for Celgene Corp. (NASDAQ:CELG) (?)
Ratings Breakdown: 3 Hold Ratings, 23 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $139.09 (29.96% upside)

Analysts' Ratings History for Celgene Corp. (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetDetails
8/31/2016Morgan StanleyReiterated RatingEqual Weight$120.00View Rating Details
8/25/2016Cowen and CompanyReiterated RatingOutperform$150.00View Rating Details
8/23/2016BMO Capital MarketsReiterated RatingOutperform$141.00View Rating Details
8/23/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/21/2016BTIG ResearchReiterated RatingBuy$138.00View Rating Details
8/19/2016JPMorgan Chase & Co.Reiterated RatingOverweight$136.00View Rating Details
8/15/2016Piper Jaffray Cos.Set Price TargetBuy$145.00View Rating Details
8/2/2016Stifel NicolausReiterated RatingBuy$138.00View Rating Details
8/1/2016Leerink SwannReiterated RatingMarket Perform$125.00 -> $135.00View Rating Details
7/26/2016Robert W. BairdReiterated RatingOutperform$162.00View Rating Details
7/26/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
7/17/2016Canaccord GenuityReiterated RatingOutperform$156.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingOutperform$140.00View Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00View Rating Details
6/13/2016Barclays PLCReiterated RatingPositiveView Rating Details
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
6/8/2016Bank of America Corp.Reiterated RatingBuy$125.00View Rating Details
5/25/2016William BlairReiterated RatingOutperformView Rating Details
5/18/2016ArgusReiterated RatingBuy$155.00View Rating Details
4/28/2016Raymond James Financial Inc.Reiterated RatingBuyView Rating Details
4/28/2016SunTrust Banks Inc.Reiterated RatingBuy$145.00 -> $147.00View Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$130.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$90.00 -> $83.00View Rating Details
1/29/2016Royal Bank Of CanadaLower Price TargetOutperform$150.00 -> $135.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
1/14/2016Standpoint ResearchInitiated CoverageBuy$130.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralView Rating Details
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00View Rating Details
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00View Rating Details
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00View Rating Details
1/30/2015S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
(Data available from 8/31/2014 forward)

Earnings

Earnings History for Celgene Corp. (NASDAQ:CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.22$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$1.06$1.07$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.99$1.01$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.95$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.89$0.90$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corp. (NASDAQ:CELG)
Current Year EPS Consensus Estimate: $5.11 EPS
Next Year EPS Consensus Estimate: $6.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.09$1.09$1.09
Q2 20162$1.25$1.26$1.26
Q3 20162$1.28$1.32$1.30
Q4 20162$1.35$1.39$1.37
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corp. (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celgene Corp. (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celgene Corp. (NASDAQ:CELG)
DateHeadline
businesswire.com logoFORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for Nash Compound in Strategic Alliance with Celgene Corporation (NASDAQ:CELG)
www.businesswire.com - August 31 at 8:55 AM
capitalcube.com logoCelgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : August 31, 2016 (NASDAQ:CELG)
www.capitalcube.com - August 31 at 8:55 AM
smarteranalyst.com logoMorgan Stanley Chimes in on Celgene Corporation (CELG) Ahead of GED-0301 Topline Data (NASDAQ:CELG)
www.smarteranalyst.com - August 30 at 12:02 PM
News IconCelgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September (NASDAQ:CELG)
ih.advfn.com - August 29 at 8:53 AM
blogs.barrons.com logoBiotech Stocks: Oops, She Did It Again (NASDAQ:CELG)
blogs.barrons.com - August 25 at 4:11 PM
News IconCelgene Corporation (NASDAQ:CELG) from Biotechnology – Todays Top Gains (NASDAQ:CELG)
twincountynews.com - August 25 at 9:01 AM
247wallst.com logoShort Sellers Increase Bets in Major Biotechs (NASDAQ:CELG)
247wallst.com - August 25 at 9:01 AM
News IconJefferies Group Reiterates Buy at Celgene Corp. (NASDAQ: CELG) - BNB Daily (blog) (NASDAQ:CELG)
www.baseball-news-blog.com - August 24 at 4:06 PM
smarteranalyst.com logoCowen Top Analyst Chimes In on Celgene Corporation (CELG) Following Drug Price Hikes (NASDAQ:CELG)
www.smarteranalyst.com - August 24 at 4:06 PM
fool.com logoDear Pfizer, Stop Overpaying for Acquisitions! (NASDAQ:CELG)
www.fool.com - August 24 at 4:06 PM
News IconResearch Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health (NASDAQ:CELG)
www.kswo.com - August 24 at 11:37 AM
News IconCelgene Corp.'s (CELG) Buy Rating Reaffirmed at BTIG Research (NASDAQ:CELG)
larampadinapoli.com - August 23 at 9:21 PM
finance.yahoo.com logoMylan price hike happy? (NASDAQ:CELG)
finance.yahoo.com - August 23 at 9:21 PM
smarteranalyst.com logoBMO Weighs in on Celgene Corporation (CELG) Ahead of Mongersen Phase 2 Data (NASDAQ:CELG)
www.smarteranalyst.com - August 23 at 4:16 PM
thecountrycaller.com logoCelgene Corporation (CELG): Here's What to Expect From Mongersen's Phase II Trial (NASDAQ:CELG)
www.thecountrycaller.com - August 23 at 8:18 AM
marketexclusive.com logoCelgene Corporation (NASDAQ:CELG) Teams Up With Olympic Swimmer On Psoriasis Awareness (NASDAQ:CELG)
marketexclusive.com - August 23 at 8:18 AM
fool.com logoHere's Why a Gilead Stock Split Is Unlikely (NASDAQ:CELG)
www.fool.com - August 22 at 4:12 PM
thestreet.com logoMedivation Scores Premium in Sale to Pfizer (NASDAQ:CELG)
www.thestreet.com - August 22 at 4:12 PM
business.financialpost.com logoPfizer Inc to buy Medivation in $14-billion deal (NASDAQ:CELG)
business.financialpost.com - August 22 at 8:54 AM
bloomberg.com logoFrom Nightmare Drug to Celgene Blockbuster, Thalidomide Is Back (NASDAQ:CELG)
www.bloomberg.com - August 22 at 8:54 AM
News IconBiotechnology: Celgene Corporation (NASDAQ:CELG) Position of the day (NASDAQ:CELG)
twincountynews.com - August 19 at 4:49 PM
smarteranalyst.com logoJ.P. Morgan Highlights The 20 Billion Dollar Celgene Corporation (CELG) Question (NASDAQ:CELG)
www.smarteranalyst.com - August 18 at 8:48 PM
marketrealist.com logoDespite Competitive Pressures, CELG Leads in Hematologic Oncology (NASDAQ:CELG)
marketrealist.com - August 18 at 12:11 PM
reuters.com logoExclusive: Merck enters race for cancer drugmaker Medivation - sources (NASDAQ:CELG)
www.reuters.com - August 17 at 4:16 PM
News IconOlympic Swimmer And Author Teams Up With Celgene To Launch SHOW MORE OF YOU Psoriasis Campaign (NASDAQ:CELG)
www.biospace.com - August 17 at 11:55 AM
News IconTop Gainers of the Day: Celgene Corporation (NASDAQ:CELG) from Biotechnology (NASDAQ:CELG)
twincountynews.com - August 17 at 11:55 AM
marketrealist.com logoCelgene Continues to Develop Its Hematologic Oncology Pipeline (NASDAQ:CELG)
marketrealist.com - August 17 at 11:55 AM
publicnow.com logoOlympic Swimmer and Author Dara Torres Teams Up With Celgene to Launch SHOW MORE OF YOU Psoriasis Campaign (NASDAQ:CELG)
www.publicnow.com - August 17 at 11:55 AM
marketrealist.com logoCELG’s Otezla Continues Dominating US Inflammation and Immunology (NASDAQ:CELG)
marketrealist.com - August 17 at 11:55 AM
smarteranalyst.com logoPiper Jaffray Provides 2H16 Outlook for Celgene Corporation (CELG) (NASDAQ:CELG)
www.smarteranalyst.com - August 16 at 9:25 PM
marketrealist.com logoPomalyst Continues to Witness Strong Global Demand in 2016 (NASDAQ:CELG)
marketrealist.com - August 16 at 9:56 AM
News IconAnalysts Valuations For Two Stocks: Carnival Corp (NYSE:CCL), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:CELG)
voiceregistrar.com - August 15 at 4:20 PM
marketrealist.com logoRevlimid Is Expected to Become a Major Lymphoma Drug by 2020 (NASDAQ:CELG)
marketrealist.com - August 15 at 11:22 AM
News IconUpdate on Celgene Corporation (NASDAQ:CELG) for the day (NASDAQ:CELG)
twincountynews.com - August 13 at 12:05 PM
thestreet.com logoShould Gilead Split in Two? (NASDAQ:CELG)
www.thestreet.com - August 12 at 4:08 PM
marketrealist.com logoHow Do Celgene’s Valuation Multiples Compare to Its Peers’? (NASDAQ:CELG)
marketrealist.com - August 12 at 4:08 PM
marketrealist.com logoAnalysts’ Recommendations for Celgene and Its Peers in 2016 (NASDAQ:CELG)
marketrealist.com - August 12 at 4:08 PM
finance.yahoo.com logoGlobal Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets (NASDAQ:CELG)
finance.yahoo.com - August 12 at 12:32 PM
News IconWelch Forbes buys $26796402 stake in Celgene Corporation (CELG) (NASDAQ:CELG)
myhealthbowl.com - August 10 at 9:43 PM
News IconRobert J. Hugin Sells 100000 Shares of Celgene Corp. (CELG) Stock (NASDAQ:CELG)
potiner.com - August 10 at 9:43 PM
tradecalls.org logoLarge Inflow of Money Detected in Celgene Corporation - Trade Calls (NASDAQ:CELG)
www.tradecalls.org - August 10 at 11:35 AM
tradecalls.org logoLarge Inflow of Money Detected in Celgene Corporation (NASDAQ:CELG)
www.tradecalls.org - August 10 at 11:35 AM
News IconAnalysts showing optimistic trends for: Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
www.newsoracle.com - August 9 at 12:22 PM
News IconIs Celgene Corporation (NASDAQ:CELG), a large market cap stock a smart buy? (NASDAQ:CELG)
twincountynews.com - August 8 at 9:36 PM
bizjournals.com logoBIOTECH: Cancer-focused startup gets $37M stake (NASDAQ:CELG)
www.bizjournals.com - August 8 at 9:35 PM
bizjournals.com logoThis big biotech boosts its deep Bay Area cancer-fighting portfolio - San Francisco Business Times (blog) (NASDAQ:CELG)
www.bizjournals.com - August 8 at 4:15 PM
smarteranalyst.com logoCelgene Corporation (CELG) Remains Top Pick at Cowen Following Meeting with Management (NASDAQ:CELG)
www.smarteranalyst.com - August 8 at 4:15 PM
bizjournals.com logoThis big biotech boosts its deep Bay Area cancer-fighting portfolio (NASDAQ:CELG)
feeds.bizjournals.com - August 8 at 3:58 PM
fool.com logoA Trio of Catalysts Sends Celgene Corporation 14% Higher in July (NASDAQ:CELG)
www.fool.com - August 8 at 11:29 AM
fortune.com logoAnalyst Ratings On Watch List: AbbVie Inc (NYSE:ABBV), Celgene Corporation (NASDAQ:CELG) - Review Fortune (NASDAQ:CELG)
reviewfortune.com - August 8 at 8:58 AM

Social

Celgene Corp. (NASDAQ:CELG) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff